Scholarlink

<p>The management of HER2-negative metastatic breast cancer (MBC) in the second-line or later setting remains challenging, due to the absence of standardized regimens and the limited efficacy of chemotherapy. Here, we report a prospectively, single-arm, phase II study evaluating anlotinib plus chemotherapy in patients with HER2-negative MBC (<i>n</i> = 33) who had progressed after at least one prior line of systemic therapy for metastatic disease. The primary endpoints were median progression-free survival (mPFS) and overall survival (OS), while secondary endpoints included objective response rate (ORR), clinical benefit rate (CBR), disease control rate (DCR), and safety. Exploratory proteomic profiling using the Olink Target 96 Immuno-Oncology panel was performed on baseline serum samples to identify potential predictors of response. After a median follow-up of 25.9 months and the median number of prior systemic therapy lines was 2 (range, 1–4). The mPFS was 8.3 (95% CI: 6.3–10.3) months, and the mOS was 22.2(95% CI: 13.1–31.3) months. The ORR was 33.3%, DCR reached 90.9% and CBR stood at 60.6%. Proteomic analysis indicated that higher baseline serum levels of proteins including CSF-1 were associated with shorter PFS (<i>P</i> &lt; 0.05). No treatment-related fatalities were observed. This trial is registered with <a href="http://www.chictr.org.cn">www.chictr.org.cn</a> (ChiCTR2400081835) on 13 March 2024.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Phase II trial of anlotinib-chemotherapy combination in pretreated HER2-negative metastatic breast cancer: therapeutic efficacy and proteomic biomarker profiling

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年2月17日

查看全文
  • Ting Xu,
  • Quan Gu,
  • Shiyi Li,
  • Lili Zhang,
  • Yuan Yuan

摘要

The management of HER2-negative metastatic breast cancer (MBC) in the second-line or later setting remains challenging, due to the absence of standardized regimens and the limited efficacy of chemotherapy. Here, we report a prospectively, single-arm, phase II study evaluating anlotinib plus chemotherapy in patients with HER2-negative MBC (n = 33) who had progressed after at least one prior line of systemic therapy for metastatic disease. The primary endpoints were median progression-free survival (mPFS) and overall survival (OS), while secondary endpoints included objective response rate (ORR), clinical benefit rate (CBR), disease control rate (DCR), and safety. Exploratory proteomic profiling using the Olink Target 96 Immuno-Oncology panel was performed on baseline serum samples to identify potential predictors of response. After a median follow-up of 25.9 months and the median number of prior systemic therapy lines was 2 (range, 1–4). The mPFS was 8.3 (95% CI: 6.3–10.3) months, and the mOS was 22.2(95% CI: 13.1–31.3) months. The ORR was 33.3%, DCR reached 90.9% and CBR stood at 60.6%. Proteomic analysis indicated that higher baseline serum levels of proteins including CSF-1 were associated with shorter PFS (P < 0.05). No treatment-related fatalities were observed. This trial is registered with www.chictr.org.cn (ChiCTR2400081835) on 13 March 2024.